Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
shape increases » showed increases (Expand Search), sharp increase (Expand Search), disease increases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
shape increases » showed increases (Expand Search), sharp increase (Expand Search), disease increases (Expand Search)
-
2141
-
2142
-
2143
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
2144
-
2145
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2146
-
2147
-
2148
-
2149
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2150
-
2151
-
2152
-
2153
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2154
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2155
-
2156
-
2157
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2158
-
2159
-
2160